<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39335658</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>Unraveling the Impact of COVID-19 on Rheumatoid Arthritis: Insights from Two Romanian Hospitals-Preliminary Results.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2145</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines12092145</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Rheumatoid arthritis (RA) patients are at heightened risk of Coronavirus Disease-19 (COVID-19) complications due to immune dysregulation, chronic inflammation, and treatment with immunosuppressive therapies. This study aims to characterize the clinical and laboratory parameters of RA patients diagnosed with COVID-19, identify predictive risk factors for severe forms of this infection for RA patients, and determine if any RA immunosuppressive therapy is associated with worse COVID-19 outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective observational case-control study included 86 cases (43 diagnosed with RA and 43 cases without any inflammatory or autoimmune disease) that suffered from SARS-CoV-2 in two Romanian hospitals between March 2020 and February 2024. Data on demographics, RA disease characteristics, COVID-19 severity, treatment regimens, and outcomes were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">RA patients exhibited a distinct symptom profile compared to non-RA controls, with higher incidences of neurological, musculoskeletal, and gastrointestinal symptoms, while the control group showed more respiratory and systemic manifestations. Severe COVID-19 is correlated with age and laboratory markers like erythrocyte sedimentation rate (ESR), leucocytes, neutrophils, neutrophil-to-lymphocyte ratio (NLR), aspartate aminotransferase (AST), serum creatinine, and urea. Additionally, RA treatments, particularly rituximab (RTX), were associated with more severe COVID-19 outcomes (but with no statistical significance), potentially due to the advanced disease stage and comorbidities in these patients. Post-infection, a significant number of RA patients experienced disease flares, necessitating adjustments in their treatment regimens.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study underscores the complex interplay between RA and COVID-19, highlighting significant clinical heterogeneity and the need for tailored management strategies. Limitations include sample size constraints, possible selection, and information bias, as well as the lack of adjustments for potential confounding variables that hinder the ability to formulate definitive conclusions. Future research plans to expand the research group size and further elucidate these relationships.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vlădulescu-Trandafir</LastName><ForeName>Andreea-Iulia</ForeName><Initials>AI</Initials><Identifier Source="ORCID">0000-0003-1369-3873</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuromuscular Rehabilitation Clinic Division, Teaching Emergency Hospital "Bagdasar-Arseni", 041915 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onose</LastName><ForeName>Gelu</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-6346-8941</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuromuscular Rehabilitation Clinic Division, Teaching Emergency Hospital "Bagdasar-Arseni", 041915 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munteanu</LastName><ForeName>Constantin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1084-7710</Identifier><AffiliationInfo><Affiliation>Neuromuscular Rehabilitation Clinic Division, Teaching Emergency Hospital "Bagdasar-Arseni", 041915 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medical Bioengineering, University of Medicine and Pharmacy "Grigore T. Popa" Iasi, 700454 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iancu</LastName><ForeName>Ioana</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-1334-4809</Identifier><AffiliationInfo><Affiliation>Manchester Centre for Clinical Neuroscience, Manchester M6 8HD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bălănescu</LastName><ForeName>Andra-Rodica</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine and Rheumatology, "Sfânta Maria" Hospital, 011172 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Opriș-Belinski</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-3883-9672</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine and Rheumatology, "Sfânta Maria" Hospital, 011172 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berghea</LastName><ForeName>Florian</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-3405-9273</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine and Rheumatology, "Sfânta Maria" Hospital, 011172 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prefac</LastName><ForeName>Cristiana</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Rheumatology, "Sfânta Maria" Hospital, 011172 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grădinaru</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6759-0672</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine and Rheumatology, "Sfânta Maria" Hospital, 011172 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aurelian</LastName><ForeName>Sorina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3215-8892</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gerontology and Geriatrics Clinic Division, St. Luca Hospital for Chronic Illnesses, 041915 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciobanu</LastName><ForeName>Vlad</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Computer Science Department, Politehnica University of Bucharest, 060042 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bojincă</LastName><ForeName>Violeta-Claudia</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine and Rheumatology, "Sfânta Maria" Hospital, 011172 Bucharest, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">clinical characteristics</Keyword><Keyword MajorTopicYN="N">rheumatoid arthritis</Keyword><Keyword MajorTopicYN="N">severity</Keyword><Keyword MajorTopicYN="N">treatment outcomes</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39335658</ArticleId><ArticleId IdType="pmc">PMC11430409</ArticleId><ArticleId IdType="doi">10.3390/biomedicines12092145</ArticleId><ArticleId IdType="pii">biomedicines12092145</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Codreanu C., Ionescu R., Predeteanu D., Rezus E., Parvu M., Mogosan C., Popescu C.C., Rednic S. Recommendations of the Romanian Society of Rheumatology regarding the management of patients with rheumatic diseases in the context of the SARS-CoV-2 pandemic. Rom. J. Rheumatol. 2020;29:101–111. doi: 10.37897/RJR.2020.3.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.37897/RJR.2020.3.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Trandafir A.I., Onose G., Munteanu C., Băila M., Saglam A.O., Mandu M., Săulescu I., Grădinaru E., Bojincă V.-C. Particularities regarding Clinical-biological and Evolutive Parameters of Immune-mediated Rheumatic Diseases in Patients with COVID-19-systematic literature review. Balneo PRM Res. J. 2023;2023:562. doi: 10.12680/balneo.2023.562.</Citation><ArticleIdList><ArticleId IdType="doi">10.12680/balneo.2023.562</ArticleId></ArticleIdList></Reference><Reference><Citation>Robu A.M., Onose G., Ulinici M.T., Andrei R., Bălănescu A., Comănici V.D., Ciomârtan T., Codreanu I.-F. Actual data regarding the impact of viral respiratory co-infection (COVID-19 and flu/Respiratory Syncytial Virus-RSV)—A systematic review. Balneo PRM Res. J. 2024;15:1. doi: 10.12680/balneo.2024.671.</Citation><ArticleIdList><ArticleId IdType="doi">10.12680/balneo.2024.671</ArticleId></ArticleIdList></Reference><Reference><Citation>Isnardi C.A., Roberts K., Saurit V., Petkovic I., Báez R.M., Quintana R., Tissera Y., Ornella S., DAngelo Exeni M.E., Pisoni C.N., et al. Sociodemographic and clinical factors associated with poor COVID-19 outcomes in patients with rheumatic diseases: Data from the SAR-COVID Registry. Clin. Rheumatol. 2023;42:563. doi: 10.1007/s10067-022-06393-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06393-8</ArticleId><ArticleId IdType="pmc">PMC9535223</ArticleId><ArticleId IdType="pubmed">36201124</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID—Coronavirus Statistics—Worldometer.  [(accessed on 6 June 2024)].  Available online:  https://www.worldometers.info/coronavirus/#countries.</Citation></Reference><Reference><Citation>Brumă E., Onose G., Ciobanu V. Research on clinical-paraclinical and evolutive aspects in patients with post spinal cord injury (SCI) statuses and COVID-19—A systematic literature review. Balneo PRM Res. J. 2023;14:538. doi: 10.12680/balneo.2023.538.</Citation><ArticleIdList><ArticleId IdType="doi">10.12680/balneo.2023.538</ArticleId></ArticleIdList></Reference><Reference><Citation>Munteanu C., Onose G., Turnea M.A., Rotariu M. Cellular and Molecular Homeostatic Microenvironmental imbalances in Osteoarthritis and Rheumatoid Arthritis. Balneo PRM Res. J. 2023;14:564. doi: 10.12680/balneo.2023.564.</Citation><ArticleIdList><ArticleId IdType="doi">10.12680/balneo.2023.564</ArticleId></ArticleIdList></Reference><Reference><Citation>Romay-Barrero H., Herrero-López J., Llorente-González A., Corral G.M.D., Palomo-Carrión R., Martínez-Galán I. Balneotherapy and health-related quality of life in individuals with Rheumatoid arthritis: An observational study under real clinical practice conditions. Balneo PRM Res. J. 2022;13:527. doi: 10.12680/balneo.2022.527.</Citation><ArticleIdList><ArticleId IdType="doi">10.12680/balneo.2022.527</ArticleId></ArticleIdList></Reference><Reference><Citation>England B., Mikuls T. UpToDate. 2024. Epidemiology of, Risk Factors for, and Possible Causes of Rheumatoid Arthritis.  [(accessed on 25 August 2024)].  Available online:  https://www.uptodate.com/contents/epidemiology-of-risk-factors-for-and-possible-causes-of-rheumatoid-arthritis.</Citation></Reference><Reference><Citation>Berghea F., Berghea C.E., Zaharia D., Trandafir A.I., Nita E.C., Vlad V.M. Residual Pain in the Context of Selecting and Switching Biologic Therapy in Inflammatory Rheumatic Diseases. Front. Med. 2021;8:712645. doi: 10.3389/fmed.2021.712645.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.712645</ArticleId><ArticleId IdType="pmc">PMC8415826</ArticleId><ArticleId IdType="pubmed">34485342</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonek K., Roszkowski L., Massalska M., Maslinski W., Ciechomska M. Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment. Cells. 2021;10:323. doi: 10.3390/cells10020323.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020323</ArticleId><ArticleId IdType="pmc">PMC7914976</ArticleId><ArticleId IdType="pubmed">33557301</ArticleId></ArticleIdList></Reference><Reference><Citation>Bălănescu A.R., Bălănescu Ș.M. Autoimunitatea. Volume 1. Editura Medicală; Bucharest, Romania: 2019. Imunitatea Înnăscută Și Dobândită—Noțiuni Fundamentale; pp. 5–10. Mecanisme Imune În Reumatologie.</Citation></Reference><Reference><Citation>Ionescu R. Esențialul în Reumatologie. 3rd ed. Editura Amaltea; Bucharest, Romania: 2022. pp. 329–344. Boli Inflamatorii Musculare.</Citation></Reference><Reference><Citation>Ge E., Li Y., Wu S., Candido E., Wei X. Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study. PLoS ONE. 2021;16:e0258154. doi: 10.1371/journal.pone.0258154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0258154</ArticleId><ArticleId IdType="pmc">PMC8491945</ArticleId><ArticleId IdType="pubmed">34610047</ArticleId></ArticleIdList></Reference><Reference><Citation>Bournia V.K., Fragoulis G.E., Mitrou P., Mathioudakis K., Tsolakidis A., Konstantonis G., Tseti I., Vourli G., Tektonidou M.G., Paraskevis D., et al. Different COVID-19 outcomes among systemic rheumatic diseases: A nation-wide cohort study. Rheumatology. 2023;62:1047–1056. doi: 10.1093/rheumatology/keac422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac422</ArticleId><ArticleId IdType="pmc">PMC9384656</ArticleId><ArticleId IdType="pubmed">35920774</ArticleId></ArticleIdList></Reference><Reference><Citation>Saadoun D., Vieira M., Vautier M., Baraliakos X., Andreica I., da Silva J.A.P., Sousa M., Luis M., Khmelinskii N., Gracía J.M.A., et al. SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: The Euro-COVIMID multicentre cross-sectional study. Lancet Rheumatol. 2021;3:e481–e488. doi: 10.1016/S2665-9913(21)00112-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00112-0</ArticleId><ArticleId IdType="pmc">PMC8081401</ArticleId><ArticleId IdType="pubmed">33942031</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezus E., Popescu C.C., Mogosan C., Avram C., Ionitescu R.C., Felea I., Filipescu I.-C., Codreanu C. Treatment of rheumatoid arthritis with biologic targeted synthetic disease-modifying anti-rheumatic drugs in 2022-real-world data from the Romanian Registry of Rheumatic Diseases. Rom. J. Rheumatol. 2023;32:122–127. doi: 10.37897/RJR.2023.3.7.</Citation><ArticleIdList><ArticleId IdType="doi">10.37897/RJR.2023.3.7</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrino R., Pellino G., Selvaggi F., Federico A., Romano M., Gravina A.G. Therapeutic adherence recorded in the outpatient follow-up of inflammatory bowel diseases in a referral center: Damages of COVID-19. Dig. Liver Dis. 2022;54:1449–1451. doi: 10.1016/j.dld.2022.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2022.07.016</ArticleId><ArticleId IdType="pmc">PMC9375145</ArticleId><ArticleId IdType="pubmed">35973931</ArticleId></ArticleIdList></Reference><Reference><Citation>Toori K.U., Qureshi M.A., Chaudhry A., Safdar M.F. Neutrophil to lymphocyte ratio (NLR) in COVID-19: A cheap prognostic marker in a resource constraint setting. Pak. J. Med. Sci. 2021;37:1435. doi: 10.12669/pjms.37.5.4194.</Citation><ArticleIdList><ArticleId IdType="doi">10.12669/pjms.37.5.4194</ArticleId><ArticleId IdType="pmc">PMC8377926</ArticleId><ArticleId IdType="pubmed">34475926</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Liu C., Mao Z., Xiao M., Wang L., Qi S., Zhou F. Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: A systematic review and meta-analysis. Crit. Care. 2020;24:647. doi: 10.1186/s13054-020-03374-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03374-8</ArticleId><ArticleId IdType="pmc">PMC7667659</ArticleId><ArticleId IdType="pubmed">33198786</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelzo M., Cacciapuoti S., Pinchera B., De Rosa A., Cernera G., Scialò F., Mormile M., Fabbrocini G., Parrella R., Gentile I., et al. Prognostic Role of Neutrophil to Lymphocyte Ratio in COVID-19 Patients: Still Valid in Patients That Had Started Therapy? Front. Public Health. 2021;9:664108. doi: 10.3389/fpubh.2021.664108.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.664108</ArticleId><ArticleId IdType="pmc">PMC8239130</ArticleId><ArticleId IdType="pubmed">34211953</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan A.S., Rout A. Use of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in COVID-19. J. Clin. Med. Res. 2020;12:448. doi: 10.14740/jocmr4240.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jocmr4240</ArticleId><ArticleId IdType="pmc">PMC7331861</ArticleId><ArticleId IdType="pubmed">32655740</ArticleId></ArticleIdList></Reference><Reference><Citation>Filip C., Covali R., Socolov D., Akad M., Carauleanu A., Andrada Vasilache I., Scripcariu I.S., Pavaleanu I., Dumachita-Sargu G., Butureanu T., et al. The Influence of Climate on Critically Ill Pregnant COVID-19 Patients, as Revealed by the Inflammation Indexes, in Spring versus Autumn 2021 Infection. Balneo PRM Res. J. 2023;14:571. doi: 10.12680/balneo.2023.571.</Citation><ArticleIdList><ArticleId IdType="doi">10.12680/balneo.2023.571</ArticleId></ArticleIdList></Reference><Reference><Citation>Satis S. New Inflammatory Marker Associated with Disease Activity in Rheumatoid Arthritis: The Systemic Immune-Inflammation Index. Curr. Health Sci. J. 2021;47:553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8987472</ArticleId><ArticleId IdType="pubmed">35444819</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangoni A.A., Zinellu A. The diagnostic role of the systemic inflammation index in patients with immunological diseases: A systematic review and meta-analysis. Clin. Exp. Med. 2024;24:27. doi: 10.1007/s10238-024-01294-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-024-01294-3</ArticleId><ArticleId IdType="pmc">PMC10824868</ArticleId><ArticleId IdType="pubmed">38285324</ArticleId></ArticleIdList></Reference><Reference><Citation>Fois A.G., Paliogiannis P., Scano V., Cau S., Babudieri S., Perra R., Ruzzittu G., Zinellu E., Pirina P., Carru C., et al. The Systemic Inflammation Index on Admission Predicts In-Hospital Mortality in COVID-19 Patients. Molecules. 2020;25:5725. doi: 10.3390/molecules25235725.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules25235725</ArticleId><ArticleId IdType="pmc">PMC7731255</ArticleId><ArticleId IdType="pubmed">33291581</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangoni A.A., Zinellu A. Systemic inflammation index, disease severity, and mortality in patients with COVID-19: A systematic review and meta-analysis. Front. Immunol. 2023;14:1212998. doi: 10.3389/fimmu.2023.1212998.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1212998</ArticleId><ArticleId IdType="pmc">PMC10320859</ArticleId><ArticleId IdType="pubmed">37415980</ArticleId></ArticleIdList></Reference><Reference><Citation>Citu C., Gorun F., Motoc A., Sas I., Gorun O.M., Burlea B., Tuta-Sas I., Tomescu L., Neamtu R., Malita D., et al. The Predictive Role of NLR, d-NLR, MLR, and SIRI in COVID-19 Mortality. Diagnostics. 2022;12:122. doi: 10.3390/diagnostics12010122.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics12010122</ArticleId><ArticleId IdType="pmc">PMC8774862</ArticleId><ArticleId IdType="pubmed">35054289</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionescu C.E., Popescu C.C., Agache M., Dinache G., Codreanu C. Depression in Rheumatoid Arthritis: Prevalence and Effects on Disease Activity. J. Clin. Med. 2024;13:2058. doi: 10.3390/jcm13072058.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm13072058</ArticleId><ArticleId IdType="pmc">PMC11012436</ArticleId><ArticleId IdType="pubmed">38610822</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay J., Upchurch K.S. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology. 2012;51((Suppl. S6)):vi5–vi9. doi: 10.1093/rheumatology/kes279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kes279</ArticleId><ArticleId IdType="pubmed">23221588</ArticleId></ArticleIdList></Reference><Reference><Citation>IBM Corp. IBM SPSS Statistics for Windows. IBM Corp.; Armonk, NY, USA: 2023.</Citation></Reference><Reference><Citation>Váncsa S., Dembrovszky F., Farkas N., Szakó L., Teutsch B., Bunduc S., Nagy R., Párniczky A., Erőss B., Péterfi Z., et al. Repeated SARS-CoV-2 Positivity: Analysis of 123 Cases. Viruses. 2021;13:512. doi: 10.3390/v13030512.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13030512</ArticleId><ArticleId IdType="pmc">PMC8003803</ArticleId><ArticleId IdType="pubmed">33808867</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto H., Hashimoto S., Shimazaki Y. Functional Impairment and Periodontitis in Rheumatoid Arthritis. Int. Dent. J. 2022;72:641–647. doi: 10.1016/j.identj.2022.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.identj.2022.01.002</ArticleId><ArticleId IdType="pmc">PMC9485534</ArticleId><ArticleId IdType="pubmed">35241287</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Guideline Clinical Management of COVID-19 Patients: Living Guideline, 18 November 2021. 2021.  [(accessed on 7 August 2024)].  Available online:  https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2023.2.</Citation></Reference><Reference><Citation>Rodrigues H.C.N., Silva M.L., Mantovani M.D.S., Silva J.M.D., Domingues M.F.P., Tanni S.É., Azevedo P.S., Minicucci M.F., Buffarah M.N.B., Pereira A.G., et al. Higher urea-to-albumin ratio is associated with mortality risk in critically ill COVID-19 patients. Clin. Nutr. ESPEN. 2023;56:9–12. doi: 10.1016/j.clnesp.2023.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnesp.2023.04.017</ArticleId><ArticleId IdType="pmc">PMC10129333</ArticleId><ArticleId IdType="pubmed">37344090</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin J., Wang Y., Jiang H., Wu C., Sang Z., Sun W., Wei J., Wang W., Liu D., Huang H. Blood urea nitrogen and clinical prognosis in patients with COVID-19: A retrospective study. Medicine. 2024;103:E37299. doi: 10.1097/MD.0000000000037299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000037299</ArticleId><ArticleId IdType="pmc">PMC10883624</ArticleId><ArticleId IdType="pubmed">38394490</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott I.C., Whittle R., Bailey J., Twohig H., Hider S.L., Mallen C.D., Muller S., Jordan K.P. Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: An observational study using primary care electronic health record data. Lancet Reg. Health Eur. 2022;23:100519. doi: 10.1016/j.lanepe.2022.100519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2022.100519</ArticleId><ArticleId IdType="pmc">PMC9557034</ArticleId><ArticleId IdType="pubmed">36246147</ArticleId></ArticleIdList></Reference><Reference><Citation>George M.D., Venkatachalam S., Banerjee S., Baker J.F., Merkel P.A., Gavigan K., Curtis D., Danila M.I., Curtis J.R., Nowell W.B. Concerns, Healthcare Use, and Treatment Interruptions in Patients with Common Autoimmune Rheumatic Diseases During the COVID-19 Pandemic. J. Rheumatol. 2021;48:603–607. doi: 10.3899/jrheum.201017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.201017</ArticleId><ArticleId IdType="pmc">PMC8121899</ArticleId><ArticleId IdType="pubmed">33191284</ArticleId></ArticleIdList></Reference><Reference><Citation>Dernoncourt A., Schmidt J., Duhaut P., Liabeuf S., Gras-Champel V., Masmoudi K., Bennis Y., Batteux B. COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database. Fundam. Clin. Pharmacol. 2021;36:199–209. doi: 10.1111/fcp.12695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/fcp.12695</ArticleId><ArticleId IdType="pmc">PMC8239613</ArticleId><ArticleId IdType="pubmed">33973280</ArticleId></ArticleIdList></Reference><Reference><Citation>Malek Mahdavi A., Varshochi M., Hajialilo M., Dastgiri S., Khabbazi R., Khabbazi A. Factors associated with COVID-19 and its outcome in patients with rheumatoid arthritis. Clin. Rheumatol. 2021;40:4527. doi: 10.1007/s10067-021-05830-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-05830-4</ArticleId><ArticleId IdType="pmc">PMC8241410</ArticleId><ArticleId IdType="pubmed">34189674</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Iorio M., Cook C.E., Vanni K.M.M., Patel N.J., D’Silva K.M., Fu X., Wang J., Prisco L.C., Kowalski E., Zaccardelli A., et al. DMARD disruption, disease flare, and prolonged symptom duration after acute COVID-19 among participants with rheumatic disease: A prospective study. Semin. Arthritis Rheum. 2022;55:152025. doi: 10.1016/j.semarthrit.2022.152025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2022.152025</ArticleId><ArticleId IdType="pmc">PMC9116968</ArticleId><ArticleId IdType="pubmed">35617780</ArticleId></ArticleIdList></Reference><Reference><Citation>Diiorio M., Kennedy K., Liew J.W., Putman M.S., Sirotich E., Sattui S.E., Foster G., Harrison C., Larché M.J., Levine M., et al. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2022;8:e002587. doi: 10.1136/rmdopen-2022-002587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2022-002587</ArticleId><ArticleId IdType="pmc">PMC9475962</ArticleId><ArticleId IdType="pubmed">36104117</ArticleId></ArticleIdList></Reference><Reference><Citation>Tăbîrță A., Bulai M., Chihai V., Pascal O. Assessment of Musculoskeletal Pain in Medical Rehabilitation of POST-COVID-19 patient. Res. J. 2023;14:549.</Citation></Reference><Reference><Citation>Khorasanchi Z., Rashidmayvan M., Hasanzadeh E., Moghadam M.R.S.F., Afkhami N., Asadiyan-Sohan P., Fard M.V., Mohammadhasani K., Varaste N., Sharifan P., et al. The association of hematological inflammatory markers and psychological function in COVID-19 patients: A cross-sectional study. Physiol. Rep. 2023;11:e15889. doi: 10.14814/phy2.15889.</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.15889</ArticleId><ArticleId IdType="pmc">PMC10733126</ArticleId><ArticleId IdType="pubmed">38123447</ArticleId></ArticleIdList></Reference><Reference><Citation>Tezcan M.E., Acer Kasman S., Şen N., Osken S., Yılmaz-Oner S. Importance of hematological markers in familial Mediterranean fever in terms of disease severity and amyloidosis. Rheumatol. Int. 2023;43:1313–1321. doi: 10.1007/s00296-023-05290-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-023-05290-w</ArticleId><ArticleId IdType="pubmed">36879026</ArticleId></ArticleIdList></Reference><Reference><Citation>Choy M., Zhen Z., Dong B., Chen C., Dong Y., Liu C., Liang W., Xue R. Mean corpuscular haemoglobin concentration and outcomes in heart failure with preserved ejection fraction. ESC Heart Fail. 2023;10:1214–1221. doi: 10.1002/ehf2.14225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.14225</ArticleId><ArticleId IdType="pmc">PMC10053270</ArticleId><ArticleId IdType="pubmed">36695165</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W., Jiang T., Tan Y., Li C., Wu S., Mei B. Characteristics of hematological parameters on admission in COVID-19 Omicron variant infected in Chinese population: A large-scale retrospective study. BMC Infect. Dis. 2023;23:835. doi: 10.1186/s12879-023-08771-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08771-2</ArticleId><ArticleId IdType="pmc">PMC10683119</ArticleId><ArticleId IdType="pubmed">38012548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalay N., Aytekin M., Kaya M.G., Özbek K., Karayakali M., Söǧüt E., Altunkas F., Oztürk A., Koç F. The relationship between inflammation and slow coronary flow: Increased red cell distribution width and serum uric acid levels. Turk. Kardiyol. Dern. Arsivi. 2011;39:463–468. doi: 10.5543/tkda.2011.01578.</Citation><ArticleIdList><ArticleId IdType="doi">10.5543/tkda.2011.01578</ArticleId><ArticleId IdType="pubmed">21918315</ArticleId></ArticleIdList></Reference><Reference><Citation>Atwa E.T., Omar H.M., Amin A., Hammad M. Red cell distribution width and mean platelet volume in rheumatoid arthritis patients: Its association with disease activity. Reumatol. Clin. 2022;18:399–405. doi: 10.1016/j.reuma.2021.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reuma.2021.04.011</ArticleId><ArticleId IdType="pubmed">35940673</ArticleId></ArticleIdList></Reference><Reference><Citation>Balasubramaniam S., Raju B.P., Kumarasamy S.P., Ramasubramanian S., Srinivasan A.K., Gopinath I., Shanmugam K., Kumar A.S., Visakan Sivasakthi V., Srinivasan S. Lung Involvement Patterns in COVID-19: CT Scan Insights and Prognostic Implications From a Tertiary Care Center in Southern India. Cureus. 2024;16:e53335. doi: 10.7759/cureus.53335.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.53335</ArticleId><ArticleId IdType="pmc">PMC10907113</ArticleId><ArticleId IdType="pubmed">38435896</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliore M. Ground glass opacities of the lung before, during and post COVID-19 pandemic. Ann. Transl. Med. 2021;9:1042. doi: 10.21037/atm-21-2095.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm-21-2095</ArticleId><ArticleId IdType="pmc">PMC8339874</ArticleId><ArticleId IdType="pubmed">34422954</ArticleId></ArticleIdList></Reference><Reference><Citation>Bournia V.K., Fragoulis G.E., Mitrou P., Mathioudakis K., Konstantonis G., Tektonidou M.G., Tsolakidis A., Paraskevis D., Sfikakis P.P. Outcomes of COVID-19 Omicron variant in patients with rheumatoid arthritis: A nationwide Greek cohort study. Rheumatology. 2024;63:1130. doi: 10.1093/rheumatology/kead354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kead354</ArticleId><ArticleId IdType="pmc">PMC10986801</ArticleId><ArticleId IdType="pubmed">37467059</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y.Q., Liu Y.Q., Chen Z.Y., Li H., Xiao T. Rheumatoid arthritis and osteoporosis: A bi-directional Mendelian randomization study. Aging. 2021;13:14109–14130. doi: 10.18632/aging.203029.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.203029</ArticleId><ArticleId IdType="pmc">PMC8202858</ArticleId><ArticleId IdType="pubmed">34015765</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolfes M.C., Juhn Y.J., Wi S.I., Sheen Y.H. Asthma and the Risk of Rheumatoid Arthritis: An Insight into the Heterogeneity and Phenotypes of Asthma. Tuberc. Respir. Dis. 2017;80:113. doi: 10.4046/trd.2017.80.2.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.4046/trd.2017.80.2.113</ArticleId><ArticleId IdType="pmc">PMC5392483</ArticleId><ArticleId IdType="pubmed">28416952</ArticleId></ArticleIdList></Reference><Reference><Citation>Conigliaro P., D’Antonio A., Pinto S., Chimenti M.S., Triggianese P., Rotondi M., Perricone R. Autoimmune thyroid disorders and rheumatoid arthritis: A bidirectional interplay. Autoimmun. Rev. 2020;19:102529. doi: 10.1016/j.autrev.2020.102529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102529</ArticleId><ArticleId IdType="pubmed">32234405</ArticleId></ArticleIdList></Reference><Reference><Citation>Figus F.A., Piga M., Azzolin I., McConnell R., Iagnocco A. Rheumatoid arthritis: Extra-articular manifestations and comorbidities. Autoimmun. Rev. 2021;20:102776. doi: 10.1016/j.autrev.2021.102776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102776</ArticleId><ArticleId IdType="pubmed">33609792</ArticleId></ArticleIdList></Reference><Reference><Citation>Minca D., Minca A., Ionescu C.E., Dinache O.G., Popescu C., Agache M., Enache L., Mogosan C., Codreanu C. POS1205 COVID-19 in Patients with Inflammatory Rheumatic Diseases—Data from the Romanian Registry of Rheumatic Diseases. Ann. Rheum. Dis. 2022;81((Suppl. S1)):931. doi: 10.1136/annrheumdis-2022-eular.961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-eular.961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekin A., Coskun B.N., Dalkilic E., Pehlivan Y. The effects of COVID-19 infection on the mortality of patients receiving rituximab therapy. Ir. J. Med. Sci. 2023;192:1959–1973. doi: 10.1007/s11845-022-03193-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11845-022-03193-6</ArticleId><ArticleId IdType="pmc">PMC9579651</ArticleId><ArticleId IdType="pubmed">36258064</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N., Madhira V., Hu C., Olex A.L., Bergquist T., Fitzgerald K.C., Huling J.D., Patel R.C., Singh J.A. Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective nationally sampled cohort study from the, U.S. National COVID Cohort Collaborative (N3C) Semin. Arthritis Rheum. 2023;58:152149. doi: 10.1016/j.semarthrit.2022.152149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2022.152149</ArticleId><ArticleId IdType="pmc">PMC9729169</ArticleId><ArticleId IdType="pubmed">36516563</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>